Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by Stanford University.
Recruitment status was Recruiting
Information provided by:
First received: June 14, 2010
Last updated: August 9, 2010
Last verified: August 2010
The objective of this study is to better understand the underlying pathogenetic mechanisms of MPDs. We will collect peripheral blood samples from MPD patients and utilize multiparameter phospho-specific flow cytometry to investigate dysregulated signaling in blood cells from these patients. This will provide deeper insights into the pathogenesis of MPDs and may lead to the identification of novel targets for therapeutic intervention.
Myeloproliferative Disorders (MPD)
||Observational Model: Cohort
Time Perspective: Prospective
||Investigation of Dysregulated Signaling in Myeloproliferative Disorders Via Multiparameter Phospho-specific Flow Cytometry
Biospecimen Retention: Samples Without DNA
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||August 2011 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Any patient who carries a diagnosis of a myeloproliferative disorder (MPD).
Inclusion Criteria:Any patient who carries a diagnosis of a myeloproliferative disorder (MPD).
Exclusion Criteria:Any patient who is not willing to give consent.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01144780
|Stanford University School of Medicine
|Stanford, California, United States, 94305 |
|Contact: Stephen Oh 650-723-7875 firstname.lastname@example.org |
|Contact: Cancer Clinical Trials Office (650) 498-7061 |
|Principal Investigator: Jason Robert Gotlib |
|Principal Investigator: Stephen Tracy Oh |
||Jason Robert Gotlib
||Stephen Tracy Oh
No publications provided
||Jason Robert Gotlib, Stanford University School of Medicine
History of Changes
|Other Study ID Numbers:
|Study First Received:
||June 14, 2010
||August 9, 2010
||United States: Institutional Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 06, 2014
Bone Marrow Diseases